TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.

Alban Bessede Florent Peyraud Benjamin Besse Sophie Cousin Mathilde Cabart François Chomy Christophe Rey Oren Lara Ophélie Odin Imane Nafia Lucile Vanhersecke Fabrice Barlesi Jean-Philippe Guégan Antoine Italiano

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our results suggest an important contribution of TROP2 expression to the primary resistance to PD-L1 blockade in NSCLC. TROP2-biomarker-based strategy may be relevant in selecting NSCLC patients who are more likely to benefit from a combination of immunotherapy and an anti-TROP2 agent.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
poor prognosis
peritoneal dialysis
binding protein
patient reported outcomes
brain metastases